RE:313 millions shares outstanding... Let's get to $5 first, which is kinda where SESN settled based on NMIBC focus before they imploded. A BTD could get us to $5 range in the hopes of a JV or buyout. Their corporate presentation still binds the top end total market at ~$2B for BCG resistant NMIBC. I missed the expansion to $5B total available market. I don't see it in their June 28th release. Can you provide a link please?
FWIW, Pfizer has been around 100+ years, had $100B+ revenue and 20+ drugs for oncology ALONE. So 20X the share count of TLT is justified with that kind of revenue. If the new class of Osmium based PDCs become a "thing", who knows.